NO20075655L - Terapeutisk RNAI for respiratorisk virusinfeksjon - Google Patents
Terapeutisk RNAI for respiratorisk virusinfeksjonInfo
- Publication number
- NO20075655L NO20075655L NO20075655A NO20075655A NO20075655L NO 20075655 L NO20075655 L NO 20075655L NO 20075655 A NO20075655 A NO 20075655A NO 20075655 A NO20075655 A NO 20075655A NO 20075655 L NO20075655 L NO 20075655L
- Authority
- NO
- Norway
- Prior art keywords
- viral infection
- respiratory viral
- therapeutic rnai
- rnai
- therapeutic
- Prior art date
Links
- 108091030071 RNAI Proteins 0.000 title 1
- 206010062106 Respiratory tract infection viral Diseases 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 abstract 2
- 230000009368 gene silencing by RNA Effects 0.000 abstract 2
- 108091027967 Small hairpin RNA Proteins 0.000 abstract 1
- 108020004459 Small interfering RNA Proteins 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 230000000840 anti-viral effect Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 239000004055 small Interfering RNA Substances 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66994205P | 2005-04-08 | 2005-04-08 | |
| PCT/US2006/013374 WO2006110688A2 (en) | 2005-04-08 | 2006-04-07 | Rnai therapeutic for respiratory virus infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20075655L true NO20075655L (no) | 2007-11-13 |
Family
ID=37087607
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20075655A NO20075655L (no) | 2005-04-08 | 2007-11-06 | Terapeutisk RNAI for respiratorisk virusinfeksjon |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20100254945A1 (https=) |
| EP (1) | EP1874802A2 (https=) |
| JP (1) | JP2008535496A (https=) |
| KR (1) | KR20070118703A (https=) |
| CN (1) | CN101184839A (https=) |
| AU (1) | AU2006235364A1 (https=) |
| CA (1) | CA2603842A1 (https=) |
| NO (1) | NO20075655L (https=) |
| NZ (1) | NZ563845A (https=) |
| WO (1) | WO2006110688A2 (https=) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7297786B2 (en) | 2004-07-09 | 2007-11-20 | University Of Iowa Research Foundation | RNA interference in respiratory epitheial cells |
| AU2006277679B2 (en) * | 2005-03-31 | 2012-08-02 | Ronen Kahana | Creating poultry and other animals resistant to viral disease |
| PL2308514T3 (pl) | 2007-03-23 | 2013-11-29 | To Bbb Holding B V | Koniugaty do ukierunkowanego dostarczania leku poprzez barierę krew-mózg |
| US20100190842A1 (en) * | 2007-04-12 | 2010-07-29 | Alnylam Pharmaceuticals, Inc. | Influenza polynucleotides, expression constructs, compositions, and methods of use |
| JP2010527914A (ja) * | 2007-04-26 | 2010-08-19 | クォーク ファーマシューティカルズ インコーポレーティッド | 呼吸器系への抑制性核酸分子の治療的送達 |
| US20100286238A1 (en) * | 2007-05-15 | 2010-11-11 | Rivory Laurent Pierre | Suppression of viruses involved in respiratory infection or disease |
| NZ581542A (en) * | 2007-05-16 | 2012-02-24 | Mat Malta Advanced Technologies Ltd | Treatment and prevention of influenza |
| JP2010528619A (ja) * | 2007-05-31 | 2010-08-26 | ベクトン・ディキンソン・アンド・カンパニー | インフルエンザａおよびインフルエンザｂウイルスを検出するための配列および方法 |
| EP3000885B1 (en) | 2009-12-18 | 2018-07-25 | Arrowhead Pharmaceuticals, Inc. | Organic compositions to treat hsf1-related diseases |
| DK2631291T3 (da) | 2010-10-22 | 2019-06-11 | Olix Pharmaceuticals Inc | Nukleinsyremolekyler, der inducerer rna-interferens, og anvendelser deraf |
| US10059746B2 (en) | 2011-04-04 | 2018-08-28 | University Of Iowa Research Foundation | Methods of improving vaccine immunogenicity |
| WO2013012835A2 (en) * | 2011-07-18 | 2013-01-24 | Oregon Health & Science University | Sirna useful in the treatment of flavivirus infection |
| CA3185394A1 (en) | 2011-09-02 | 2013-03-07 | Arrowhead Pharmaceuticals, Inc. | Organic compositions to treat hsf1-related diseases |
| KR101567576B1 (ko) * | 2012-05-22 | 2015-11-10 | 올릭스 주식회사 | 세포 내 관통능을 가지고 ｒｎａ 간섭을 유도하는 핵산 분자 및 그 용도 |
| BR112015009103A2 (pt) * | 2012-10-23 | 2017-07-04 | Harrisvaccines Inc | método para proteger um animal invertebrado aquático contra o vírus da mionecrose infecciosa (imnv), método para produzir um composição e composição |
| CN103966212A (zh) * | 2013-02-06 | 2014-08-06 | 霍晋 | A型流感病毒NP基因有干扰作用的siRNA序列的设计及应用 |
| WO2014138792A1 (en) * | 2013-03-14 | 2014-09-18 | Commonwealth Scientific And Industrial Research Organisation | Double-stranded rna |
| JP7027311B2 (ja) | 2015-11-16 | 2022-03-01 | オリックス ファーマシューティカルズ，インコーポレーテッド | ＭｙＤ８８又はＴＬＲ３を標的とするＲＮＡ複合体を使用した加齢黄斑変性の治療 |
| CN108779464B (zh) | 2016-02-02 | 2022-05-17 | 奥利克斯医药有限公司 | 使用靶向angpt2和pdgfb的rna复合物治疗血管生成相关性疾病 |
| JP6944942B2 (ja) | 2016-02-02 | 2021-10-06 | オリックス ファーマシューティカルズ，インコーポレーテッド | ＩＬ４Ｒα、ＴＲＰＡ１、またはＦ２ＲＬ１を標的とするＲＮＡ複合体を用いたアトピー性皮膚炎および喘息の治療 |
| US12522827B2 (en) | 2016-03-02 | 2026-01-13 | The Board Of Trustees Of The Leland Stanford Junior University | Pan-genotypic agents against influenza virus and methods of using the same |
| US11339392B2 (en) | 2016-03-02 | 2022-05-24 | The Board Of Trustees Of The Leland Stanford Junior University | Pan-genotypic agents against influenza virus and methods of using the same |
| WO2021201996A1 (en) * | 2020-02-14 | 2021-10-07 | The Board Of Trustees Of The Leland Stanford Junior University | Pan-genotypic agents against respiratory viruses and methods of using the same |
| EP3800257B1 (en) * | 2016-03-02 | 2024-05-01 | The Board of Trustees of the Leland Stanford Junior University | Pan-genotypic agents against influenza virus and methods of using the same |
| JP7049262B2 (ja) | 2016-04-11 | 2022-04-06 | オリックス ファーマシューティカルズ，インコーポレーテッド | 結合組織成長因子を標的とするｒｎａ複合体を用いた特発性肺胞線維症の治療 |
| KR101916652B1 (ko) | 2016-06-29 | 2018-11-08 | 올릭스 주식회사 | 작은 간섭 rna의 rna 간섭효과 증진용 화합물 및 이의 용도 |
| EP3580339A4 (en) | 2017-02-10 | 2020-12-23 | Research & Business Foundation Sungkyunkwan University | LONG DOUBLE STRAND RNA FOR RNA INTERFERENCE |
| US11952631B2 (en) * | 2017-10-09 | 2024-04-09 | Medizinische Hochschule Hannover | Diagnostics and therapy for human respiratory syncytial virus |
| WO2019195936A1 (en) * | 2018-04-10 | 2019-10-17 | Ilkow Carolina Solange | Microrna-based compositions and methods used in disease treatment |
| US11702709B2 (en) * | 2021-02-09 | 2023-07-18 | Pathogendx, Inc. | Combinatorial microarray assay for clade variant detection |
| CN115120608A (zh) * | 2021-03-26 | 2022-09-30 | 圣诺生物医药技术(苏州)有限公司 | 一种siRNA药物、药物组合物、siRNA-小分子药物偶联物及其应用 |
| EP4562157A1 (en) * | 2022-07-28 | 2025-06-04 | New York University | Targeting long non-coding rna chromr in interferon-mediated inflammation in humans |
| EP4527927A1 (en) * | 2023-09-22 | 2025-03-26 | Medizinische Hochschule Hannover | Oligonucleotide-based strategies to combat respiratory viruses |
| CN118800477B (zh) * | 2024-07-11 | 2025-05-02 | 中国人民解放军军事科学院军事医学研究院 | 禽源性流感病毒溢出风险评估方法、设备、介质及产品 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) * | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4876187A (en) * | 1985-12-05 | 1989-10-24 | Meiogenics, Inc. | Nucleic acid compositions with scissile linkage useful for detecting nucleic acid sequences |
| US5011769A (en) | 1985-12-05 | 1991-04-30 | Meiogenics U.S. Limited Partnership | Methods for detecting nucleic acid sequences |
| US5403711A (en) * | 1987-11-30 | 1995-04-04 | University Of Iowa Research Foundation | Nucleic acid hybridization and amplification method for detection of specific sequences in which a complementary labeled nucleic acid probe is cleaved |
| US5185243A (en) | 1988-08-25 | 1993-02-09 | Syntex (U.S.A.) Inc. | Method for detection of specific nucleic acid sequences |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US5800992A (en) | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
| US5744101A (en) * | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
| US5573907A (en) * | 1990-01-26 | 1996-11-12 | Abbott Laboratories | Detecting and amplifying target nucleic acids using exonucleolytic activity |
| US5538848A (en) * | 1994-11-16 | 1996-07-23 | Applied Biosystems Division, Perkin-Elmer Corp. | Method for detecting nucleic acid amplification using self-quenching fluorescence probe |
| WO1995014106A2 (en) | 1993-11-17 | 1995-05-26 | Id Biomedical Corporation | Cycling probe cleavage detection of nucleic acid sequences |
| WO1995021271A1 (en) * | 1994-02-07 | 1995-08-10 | Molecular Tool, Inc. | Ligase/polymerase-mediated genetic bit analysistm of single nucleotide polymorphisms and its use in genetic analysis |
| AU713667B2 (en) * | 1996-04-12 | 1999-12-09 | Phri Properties, Inc. | Detection probes, kits and assays |
| US6037130A (en) * | 1998-07-28 | 2000-03-14 | The Public Health Institute Of The City Of New York, Inc. | Wavelength-shifting probes and primers and their use in assays and kits |
| US20030087851A1 (en) * | 1999-01-20 | 2003-05-08 | Biozak, Inc. | Pharmaceutical composition for treating or preventing influenza, and novel oligonucleotide |
| US6277607B1 (en) | 1999-05-24 | 2001-08-21 | Sanjay Tyagi | High specificity primers, amplification methods and kits |
| EP1081496A1 (en) * | 1999-08-31 | 2001-03-07 | Becton, Dickinson and Company | Flow-through assay for visually detecting the presence of influenza A and B |
| EP1546344A4 (en) * | 2002-09-18 | 2007-10-03 | Isis Pharmaceuticals Inc | EFFICIENT PRODUCTION OF TARGET RNAS USING SINGLE AND DOUBLE-STRONG OLIGOMER COMPOUNDS |
| US20040242518A1 (en) * | 2002-09-28 | 2004-12-02 | Massachusetts Institute Of Technology | Influenza therapeutic |
| US20050008617A1 (en) * | 2002-09-28 | 2005-01-13 | Massachusetts Institute Of Technology | Compositions and methods for delivery of short interfering RNA and short hairpin RNA |
| US20060160759A1 (en) * | 2002-09-28 | 2006-07-20 | Jianzhu Chen | Influenza therapeutic |
| US9486070B2 (en) | 2012-10-10 | 2016-11-08 | Stirworks Inc. | Height-adjustable support surface and system for encouraging human movement and promoting wellness |
-
2006
- 2006-04-07 AU AU2006235364A patent/AU2006235364A1/en not_active Abandoned
- 2006-04-07 WO PCT/US2006/013374 patent/WO2006110688A2/en not_active Ceased
- 2006-04-07 KR KR1020077025995A patent/KR20070118703A/ko not_active Withdrawn
- 2006-04-07 CN CNA2006800114415A patent/CN101184839A/zh active Pending
- 2006-04-07 CA CA002603842A patent/CA2603842A1/en not_active Abandoned
- 2006-04-07 EP EP06749684A patent/EP1874802A2/en not_active Withdrawn
- 2006-04-07 JP JP2008505634A patent/JP2008535496A/ja active Pending
- 2006-04-07 NZ NZ563845A patent/NZ563845A/xx not_active IP Right Cessation
- 2006-04-07 US US11/910,971 patent/US20100254945A1/en not_active Abandoned
-
2007
- 2007-11-06 NO NO20075655A patent/NO20075655L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2006235364A1 (en) | 2006-10-19 |
| EP1874802A2 (en) | 2008-01-09 |
| NZ563845A (en) | 2010-09-30 |
| US20100254945A1 (en) | 2010-10-07 |
| WO2006110688A3 (en) | 2008-01-10 |
| WO2006110688A2 (en) | 2006-10-19 |
| CN101184839A (zh) | 2008-05-21 |
| CA2603842A1 (en) | 2006-10-19 |
| JP2008535496A (ja) | 2008-09-04 |
| WO2006110688A9 (en) | 2007-03-15 |
| KR20070118703A (ko) | 2007-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20075655L (no) | Terapeutisk RNAI for respiratorisk virusinfeksjon | |
| CY1114356T1 (el) | Αναστολεις του ιου της ηπατιτιδας c | |
| EA200702493A1 (ru) | Соединения и способы лечения или предотвращения флавивирусных инфекций | |
| MA32634B1 (fr) | Polytherapie destinee a traiter une infection par le vhc | |
| NO20045247L (no) | Nukleosidderivater for behandling av hepatitt C-virusinfeksjon | |
| ATE512976T1 (de) | Hemmer des hepatitis-c-virus | |
| WO2009123776A3 (en) | Antiviral drugs for treatment of arenavirus infection | |
| EA202190473A3 (ru) | Противовирусная терапия | |
| HRP20070435A9 (en) | Tricyclic-nucleoside compounds for treating viral infections | |
| EA200900298A1 (ru) | Ингибиторы вируса гепатита с | |
| EA201071315A1 (ru) | Ингибиторы протеазы вируса гепатита с | |
| NZ593111A (en) | Antibacterial compounds | |
| NO20083427L (no) | Cystoksiske midler omfattende nye tomaymycinderivater og deres terapeutiske anvendelse | |
| NO20062146L (no) | Nukleosidforbindelser for behandling av virusinfeksjoner | |
| TW200510325A (en) | 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof | |
| SG163517A1 (en) | Antiviral compounds and methods | |
| MX2013003634A (es) | Derivados policiclicos heterociclicos y metodos de uso de los mismos para el tratamiento de enfermedades virales. | |
| EA200901241A1 (ru) | Соединения для лечения гепатита с | |
| NO20083245L (no) | Sykliske antimikrobielle peptider | |
| MY141003A (en) | Materials and methods for treating viral infections with a cysteamine compound | |
| MXPA05010440A (es) | Amidas del acido isoquinolina-5-sulfonico como inhibidores de la akt (proteina quinasa b). | |
| EA200970586A1 (ru) | Антитела к цитомегаловирусу человека (hcmv) | |
| ATE462438T1 (de) | Verwendung von carrageenan zur behandlung von rhinovirus-infektionen | |
| NZ510369A (en) | Use of heteroaryl substituted N-(indole-2-carbonyl-) amides for treatment of infection | |
| EA201170484A1 (ru) | Терапевтический режим лечения гепатита, включающий пэг-интерферон, рибавирин и vx-950 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |